Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02934568
Title Ribociclib (LEE011) Rollover Study for Continued Access
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Ribociclib

Age Groups: senior | adult | child
Covered Countries USA | FRA | ESP

Facility Status City State Zip Country Details
University of Alabama at Birmingham Birmingham Alabama 35294-3300 United States Details
Dana Farber Cancer Institute Main Site Boston Massachusetts 02215 United States Details
The Regents of the University of Michigan Ann Arbor Michigan 48109-5930 United States Details
Broome Oncology SC-2 Johnson City New York 13790 United States Details
St Jude Children's Research Hospital Memphis Tennessee 38105 United States Details
Novartis Investigative Site Villejuif Cedex Villejuif 94800 France Details
Novartis Investigative Site Lyon Cedex 69373 France Details
Novartis Investigative Site Singapore 119228 Singapore Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site Madrid 28050 Spain Details
Novartis Investigative Site Tainan 70403 Taiwan Details
Novartis Investigative Site Taipei 10002 Taiwan Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field